RiMO-501

N/A

Report date: 2025/01/26 19:35:31
NME

Base Information

Drug NameRiMO-501
Drug Alias Namedual radiosensitizer/IDO checkpoint inhibitor (University of Chicago/RiMO Therapeutics)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionIndoleamine 2,3-dioxygenase inhibitors
TargetsIndoleamine 2,3-dioxygenase
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesThe University Of Chicago
China Registration ClassN/A

Develop Information

Active CompaniesRimo Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A